Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor used as a targeted therapy for the treatment of various cancers, including ovarian, breast, pancreatic, and prostate cancer, particularly in… Read more

![Chemical structure of 4-(3-(1H-Benzo[d][1,2,3]triazole-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2147733-69-3-4-3-1H-Benzod123triazole-1-carbonyl-4-fluorobenzylphthalazin-12H-one.png&w=3840&q=75)
![Chemical structure of 4-(3-(4-((1H-Benzo[d][1,2,3]triazol-4-yl)(cyclopropyl)methyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F4-3-4-1H-Benzod123triazol-4-ylcyclopropylmethylpiperazine-1-carbonyl-4-fluorobenzylphthalazin-12H-one.png&w=3840&q=75)
![Chemical structure of 4-(3-(4-(1-(Cyclopropanecarbonyl)-1H-benzo[d][1,2,3]triazol-4-yl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F4-3-4-1-Cyclopropanecarbonyl-1H-benzod123triazol-4-ylpiperazine-1-carbonyl-4-fluorobenzylphthalazin-12H-one.png&w=3840&q=75)
![Chemical structure of 4-(3-(4-(4-(Cyclopropanecarbonyl)-1H-benzo[d][1,2,3]triazol-5-yl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F4-3-4-4-Cyclopropanecarbonyl-1H-benzod123triazol-5-ylpiperazine-1-carbonyl-4-fluorobenzylphthalazin-12H-one.png&w=3840&q=75)
![Chemical structure of 4-(3-(4-(7-(Cyclopropanecarbonyl)-1H-benzo[d][1,2,3]triazol-5-yl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F4-3-4-7-Cyclopropanecarbonyl-1H-benzod123triazol-5-ylpiperazine-1-carbonyl-4-fluorobenzylphthalazin-12H-one.png&w=3840&q=75)













![Chemical structure of 4-(4-(4-(Cyclopropanecarbonyl)-1H-benzo[d][1,2,3]triazol-1-yl)-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F4-4-4-Cyclopropanecarbonyl-1H-benzod123triazol-1-yl-3-piperazine-1-carbonylbenzylphthalazin-12H-one.png&w=3840&q=75)






























Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor used as a targeted therapy for the treatment of various cancers, including ovarian, breast, pancreatic, and prostate cancer, particularly in patients with BRCA mutations. By inhibiting PARP enzymes, this drug blocks the repair of DNA single-strand breaks, inducing synthetic lethality in cancer cells that are already deficient in homologous recombination repair pathways. Pharmaceutical reference standards for Olaparib, including its process-related impurities, degradation products, and stable isotope labelled compounds, are critical for rigorous analytical testing and quality control. These highly characterized materials are used by laboratories for impurity profiling, method validation, and stability studies to ensure the safety, therapeutic efficacy, and regulatory compliance of the active pharmaceutical ingredient. Chemists rely on these reference materials to accurately identify and quantify potential contaminants, supporting consistent drug quality throughout the pharmaceutical development lifecycle and manufacturing process.